

General information about company		Standalone
Scrip code*	540679	
NSE Symbol*	HALEOSLABS	
MSEI Symbol*	NOTLISTED	
ISIN*	INE320X01016	
Name of company	Haleos Labs Limited	
Type of company	Main Board	
Class of security	Equity	
Date of start of financial year	01-04-2025	
Date of end of financial year	31-03-2026	
Date of board meeting when results were approved	29-05-2026	
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	22-05-2026	
Description of presentation currency	INR	
Level of rounding	Lakhs	
Reporting Type	Quarterly	
Reporting Quarter	Fourth quarter	
Nature of report standalone or consolidated	Standalone	
Whether results are audited or unaudited for the quarter ended	Audited	
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Audited	
Segment Reporting	Single segment	
Description of single segment	Bulk Drugs / API's	
Start date and time of board meeting	29-05-2026 14:45	
End date and time of board meeting	29-05-2026 15:45	
Whether cash flow statement is applicable on company	Yes	
Type of cash flow statement	Cash Flow Indirect	
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion	
Whether the company has any related party?	Yes	
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes	
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA	
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA	
(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?	No	
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?		
(b) If answer to above question is No, please explain the reason for not complying.		
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?	Yes	
Latest Date on which RPT policy is updated	29-05-2025	
Indicate Company website link for updated RPT policy of the Company	https://haleoslabs.com/wp-content/uploads/2026/03/11.-Policy-on-dealing-with-Related-Party-Transactions.pdf	
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	No	
No. of times funds raised during the quarter		
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	No	No default

Financial Results – Ind-AS				
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)	
Date of start of reporting period		01-01-2026	01-04-2025	
Date of end of reporting period		31-03-2026	31-03-2026	
Whether results are audited or unaudited		Audited	Audited	
Nature of report standalone or consolidated		Standalone	Standalone	
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.			
1	Income			
	Revenue from operations	6338.42	30098.96	
	Other income	96.92	142.11	
	Total income	6435.34	30241.07	
2	Expenses			
(a)	Cost of materials consumed	3302.37	14557.49	
(b)	Purchases of stock-in-trade	0	0	
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-733.8	-650.99	
(d)	Employee benefit expense	1206.07	4939.27	
(e)	Finance costs	133.68	603.42	
(f)	Depreciation, depletion and amortisation expense	265.55	1066.4	
(g)	Other Expenses			
1	Manufacturing Expenses	1214.04	5571.54	
2	Other Expenses	729.67	1634.83	
	Total other expenses	1943.71	7206.37	
	Total expenses	6117.58	27721.96	
3	Total profit before exceptional items and tax	317.76	2519.11	
4	Exceptional items	0	0	
5	Total profit before tax	317.76	2519.11	
6	Tax expense			
7	Current tax	-92.82	532.18	
8	Deferred tax	187.12	209.25	
9	Total tax expenses	94.3	741.43	
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0	
11	Net Profit Loss for the period from continuing operations	223.46	1777.68	
12	Profit (loss) from discontinued operations before tax	0	0	
13	Tax expense of discontinued operations	0	0	
14	Net profit (loss) from discontinued operation after tax	0	0	
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0	
16	Total profit (loss) for period	223.46	1777.68	
17	Other comprehensive income net of taxes	5.21	7.81	
18	Total Comprehensive Income for the period	228.67	1785.49	
19	Total profit or loss, attributable to			
	Profit or loss, attributable to owners of parent			
	Total profit or loss, attributable to non-controlling interests			
20	Total Comprehensive income for the period attributable to			
	Comprehensive income for the period attributable to owners of parent			
	Total comprehensive income for the period attributable to owners of parent non-controlling interests			
21	Details of equity share capital			
	Paid-up equity share capital	302.33	302.33	
	Face value of equity share capital	10	10	
22	Reserves excluding revaluation reserve		19415.22	
23	Earnings per share			
i	Earnings per equity share for continuing operations			

	Basic earnings (loss) per share from continuing operations	7.39	58.8	
	Diluted earnings (loss) per share from continuing operations	7.39	58.8	
ii	Earnings per equity share for discontinued operations			
	Basic earnings (loss) per share from discontinued operations	0	0	
	Diluted earnings (loss) per share from discontinued operations	0	0	
iii	Earnings per equity share (for continuing and discontinued operations)			
	Basic earnings (loss) per share from continuing and discontinued operations	7.39	58.8	
	Diluted earnings (loss) per share from continuing and discontinued operations	7.39	58.8	
24	Debt equity ratio			Textual Information(1)
25	Debt service coverage ratio			Textual Information(2)
26	Interest service coverage ratio			Textual Information(3)
27	Disclosure of notes on financial results	Textual Information(4)		

Statement of Asset and Liabilities		
Particulars		Year ended (dd-mm-yyyy)
Date of start of reporting period		01-04-2025
Date of end of reporting period		31-03-2026
Whether results are audited or unaudited		Audited
Nature of report standalone or consolidated		Standalone
	Assets	
1	Non-current assets	
	Property, plant and equipment	18861.2
	Capital work-in-progress	130.07
	Investment property	0
	Goodwill	0
	Other intangible assets	2.24
	Intangible assets under development	
	Biological assets other than bearer plants	
	Investments accounted for using equity method	
	Non-current financial assets	
	Non-current investments	2323.17
	Trade receivables, non-current	0
	Loans, non-current	0
	Other non-current financial assets	
1	Other Financial Assets	281.5
2	Right of Use Assets	114.91
3		
4		
5		
	Details of other non-current financial assets	
	Total of other non-current financial assets	396.41
	Total non-current financial assets	2719.58
	Deferred tax assets (net)	
	Other non-current assets	
1	Other Non-Current Assets	450.2
2		
3		
4		
5		
	Details of other non-current assets	
	Total of other non-current assets	450.2
	Total non-current assets	22163.29
2	Current assets	
	Inventories	6981.3
	Current financial asset	
	Current investments	0
	Trade receivables, current	5426.43
	Cash and cash equivalents	39.89
	Bank balance other than cash and cash equivalents	116.09
	Loans, current	0
	Other current financial assets	
1		
2		
3		
4		
5		
	Details of other current financial assets	
	Total of Other current financial assets	
	Total current financial assets	5582.41

	Current tax assets (net)	152.93
	Other current assets	
1	Other Current Assets	5454.18
2		
3		
4		
5		
	Details of other current assets	
	Total of other current assets	5454.18
	Total current assets	18170.82
3	Non-current assets classified as held for sale	
4	Regulatory deferral account debit balances and related deferred tax Assets	
	Total assets	40334.11
	Equity and liabilities	
1	Equity	
	Equity attributable to owners of parent	
	Equity share capital	302.33
	Other equity	21155.36
	Total equity attributable to owners of parent	21457.69
	Non controlling interest	
	Total equity	21457.69
2	Liabilities	
	Non-current liabilities	
	Non-current financial liabilities	
	Borrowings, non-current	3518.19
	Trade Payables, non-current	
	(A) Total outstanding dues of micro enterprises and small enterprises	
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	
	Total Trade payable	
	Other non-current financial liabilities	
1	Lease Liabilities	80.97
2		
3		
4		
5		
	Details of other non-current financial liabilities	
	Total of other non-current financial liabilities	80.97
	Total non-current financial liabilities	3599.16
	Provisions, non-current	403.28
	Deferred tax liabilities (net)	1571.85
	Deferred government grants, Non-current	0
	Other non-current liabilities	
1		
2		
3		
4		
5		
	Details of other non-current liabilities	
	Total of other non-current liabilities	
	Total non-current liabilities	5574.29
	Current liabilities	
	Current financial liabilities	
	Borrowings, current	5792.61
	Trade Payables, current	
	(A) Total outstanding dues of micro enterprises and small enterprises	81.85
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	5297.47
	Total Trade payable	5379.32
	Other current financial liabilities	

1	Lease Liabilities	87.59
2	Other Financial Liabilities	1243.38
3		
4		
5		
	Details of other current financial liabilities	
	Total of other current financial liabilities	1330.97
	Total current financial liabilities	12502.9
	Other current liabilities	
1	Other Current Liabilities	614.53
2		
3		
4		
5		
	Details of other current liabilities	
	Total of other current liabilities	614.53
	Provisions, current	184.7
	Current tax liabilities (Net)	
	Deferred government grants, Current	
	Total current liabilities	13302.13
3	Liabilities directly associated with assets in disposal group classified as held for sale	
4	Regulatory deferral account credit balances and related deferred tax liability	
	Total liabilities	18876.42
	Total equity and liabilities	40334.11
	Disclosure of notes on assets and liabilities	

Other Comprehensive Income			
Date of start of reporting period		01-01-2026	01-04-2025
Date of end of reporting period		31-03-2026	31-03-2026
Whether results are audited or unaudited		Audited	Audited
Nature of report standalone or consolidated		Standalone	Standalone
	Other comprehensive income [Abstract]		
1	Amount of items that will not be reclassified to profit and loss		
	Total Amount of items that will not be reclassified to profit and loss		
2	Income tax relating to items that will not be reclassified to profit or loss		-7.35 -11.02
3	Amount of items that will be reclassified to profit and loss		
	Total Amount of items that will be reclassified to profit and loss		
4	Income tax relating to items that will be reclassified to profit or loss		2.14 3.21
5	Total Other comprehensive income		5.21 7.81

Cash flow statement, indirect		
Particulars		Year ended (dd-mm-yyyy)
Date of start of reporting period		01-04-2025
Date of end of reporting period		31-03-2026
Whether results are audited or unaudited		Audited
Nature of report standalone or consolidated		Standalone
Part I	Blue color marked fields are non-mandatory.	
1	Statement of cash flows	
	Cash flows from used in operating activities	
	Profit before tax	2519.11
2	Adjustments for reconcile profit (loss)	
	Adjustments for finance costs	0
	Adjustments for decrease (increase) in inventories	-922.92
	Adjustments for decrease (increase) in trade receivables, current	1065.83
	Adjustments for decrease (increase) in trade receivables, non-current	0
	Adjustments for decrease (increase) in other current assets	-343.69
	Adjustments for decrease (increase) in other non-current assets	-62.48
	Adjustments for other financial assets, non-current	-3.17
	Adjustments for other financial assets, current	-0.31
	Adjustments for other bank balances	0
	Adjustments for increase (decrease) in trade payables, current	780.82
	Adjustments for increase (decrease) in trade payables, non-current	0
	Adjustments for increase (decrease) in other current liabilities	295.47
	Adjustments for increase (decrease) in other non-current liabilities	0
	Adjustments for depreciation and amortisation expense	1066.4
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	0
	Adjustments for provisions, current	0
	Adjustments for provisions, non-current	0
	Adjustments for other financial liabilities, current	-57.95
	Adjustments for other financial liabilities, non-current	0
	Adjustments for unrealised foreign exchange losses gains	0
	Adjustments for dividend income	0
	Adjustments for interest income	0
	Adjustments for share-based payments	0
	Adjustments for fair value losses (gains)	0.12
	Adjustments for undistributed profits of associates	0
	Other adjustments for which cash effects are investing or financing cash flow	0
	Other adjustments to reconcile profit (loss)	-18.33
	Other adjustments for non-cash items	19.92
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships	0
	Total adjustments for reconcile profit (loss)	1819.71
	Net cash flows from (used in) operations	4338.82
	Dividends received	0
	Interest paid	-205.65
	Interest received	-7.3
	Income taxes paid (refund)	650
	Other inflows (outflows) of cash	-44.13
	Net cash flows from (used in) operating activities	3843.04
3	Cash flows from used in investing activities	
	Cash flows from losing control of subsidiaries or other businesses	0
	Cash flows used in obtaining control of subsidiaries or other businesses	0
	Other cash receipts from sales of equity or debt instruments of other entities	0
	Other cash payments to acquire equity or debt instruments of other entities	0
	Other cash receipts from sales of interests in joint ventures	0
	Other cash payments to acquire interests in joint ventures	0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0

	Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0
	Proceeds from sales of property, plant and equipment	4.52
	Purchase of property, plant and equipment	4924.47
	Proceeds from sales of investment property	0
	Purchase of investment property	0
	Proceeds from sales of intangible assets	0
	Purchase of intangible assets	0
	Proceeds from sales of intangible assets under development	0
	Purchase of intangible assets under development	0
	Proceeds from sales of goodwill	0
	Purchase of goodwill	0
	Proceeds from biological assets other than bearer plants	0
	Purchase of biological assets other than bearer plants	0
	Proceeds from government grants	0
	Proceeds from sales of other long-term assets	0
	Purchase of other long-term assets	0
	Cash advances and loans made to other parties	0
	Cash receipts from repayment of advances and loans made to other parties	0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts	0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0
	Dividends received	0
	Interest received	7.25
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	-15.2
	Net cash flows from (used in) investing activities	-4927.9
4	Cash flows from used in financing activities	
	Proceeds from changes in ownership interests in subsidiaries	0
	Payments from changes in ownership interests in subsidiaries	0
	Proceeds from issuing shares	0
	Proceeds from issuing other equity instruments	0
	Payments to acquire or redeem entity's shares	0
	Payments of other equity instruments	0
	Proceeds from exercise of stock options	0
	Proceeds from issuing debentures notes bonds etc	0
	Proceeds from borrowings	3114.2
	Repayments of borrowings	1140.35
	Payments of lease liabilities	70.84
	Dividends paid	45.35
	Interest paid	197.26
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	-575.78
	Net cash flows from (used in) financing activities	1084.62
	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes	-0.24
5	Effect of exchange rate changes on cash and cash equivalents	
	Effect of exchange rate changes on cash and cash equivalents	0
	Net increase (decrease) in cash and cash equivalents	-0.24
	Cash and cash equivalents cash flow statement at beginning of period	40.13
	Cash and cash equivalents cash flow statement at end of period	39.89

Format for Disclosure of Related Party Transactions (applicable only for half-yearly)													
Sr. No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case are due party as of the tr
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance
1	Haleos Labs Limited	AAECP4285F	Purogene Labs Private Limited	AACCR9220Q	Enterprises over which Directors or their relatives exercise significant influence	Purchase of goods or services		4000	In ordinary course of buisness and in arms length basis			1218.95	206.93
2	Haleos Labs Limited	AAECP4285F	Purogene Labs Private Limited	AACCR9220Q	Enterprises over which Directors or their relatives exercise significant influence	Sale of goods or services		3000	In ordinary course of buisness and in arms length basis			135.39	0
3	Haleos Labs Limited	AAECP4285F	Purogene Labs Private Limited	AACCR9220Q	Enterprises over which Directors or their relatives exercise significant influence	Any other transaction	Rent received	10	In ordinary course of buisness and in arms length basis			2.12	0
4	Haleos Labs Limited	AAECP4285F	Mahi Drugs Pvt Ltd	AAICM3271E	Subsidiary	Purchase of goods or services		5500	In ordinary course of buisness and in arms length basis			786.65	3587.95
5	Haleos Labs Limited	AAECP4285F	Mahi Drugs Pvt Ltd	AAICM3271E	Subsidiary	Sale of goods or services		3000	In ordinary course of buisness and in arms length basis			196.24	0
6	Haleos Labs Limited	AAECP4285F	Mahi Drugs Pvt Ltd	AAICM3271E	Subsidiary	Any other transaction	Rent received	10	In ordinary course of buisness and in arms length basis			3.19	0
7	Haleos Labs Limited	AAECP4285F	SMS Pharmaceuticals Ltd	AADCS2221D	Other Related Party	Purchase of goods or services		510	In ordinary course of buisness and in arms length basis			0	0
8	Haleos Labs Limited	AAECP4285F	SMS Pharmaceuticals Ltd	AADCS2221D	Other Related Party	Sale of goods or services		3000	In ordinary course of buisness and in arms length basis			619.39	888.4
9	Haleos Labs Limited	AAECP4285F	Chemwerth Inc	AADCC3781G	Other Related Party	Purchase of goods or services		500	In ordinary course of			0	0

									buisness and in arms length basis				
10	Haleos Labs Limited	AAECP4285F	Chemwerth Inc	AADCC3781G	Other Related Party	Sale of goods or services		2000	In ordinary course of buisness and in arms length basis			0.88	-100
11	Haleos Labs Limited	AAECP4285F	Chemwerth Inc	AADCC3781G	Other Related Party	Any other transaction	Receipt of business advance	1500	In ordinary course of buisness and in arms length basis			0	0
12	Haleos Labs Limited	AAECP4285F	TVVSN Murthy	ABKPT0255F	Key Management Personel	Remuneration			In ordinary course of buisness and in arms length basis			99.21	7.2
13	Haleos Labs Limited	AAECP4285F	T V Praveen	ACRPT0664J	Executive Director	Remuneration			In ordinary course of buisness and in arms length basis			52.35	6.1
14	Haleos Labs Limited	AAECP4285F	G Sudeepthi	AFBPT3997B	Whole Time Director	Remuneration			In ordinary course of buisness and in arms length basis			14.91	1.61
15	Mahi Drugs Private Limited	AAICM3271E	Purogene Labs Private Limited	AACCR9220Q	Enterprises over which Directors or their relatives exercise significant influence	Purchase of goods or services		500	In ordinary course of buisness and in arms length basis			13.22	0
16	Mahi Drugs Private Limited	AAICM3271E	Purogene Labs Private Limited	AACCR9220Q	Enterprises over which Directors or their relatives exercise significant influence	Sale of goods or services		500	In ordinary course of buisness and in arms length basis			0	0
17	Mahi Drugs Private Limited	AAICM3271E	Chemwerth Inc	AADCC3781G	Other Related Party	Purchase of goods or services		500	In ordinary course of buisness and in arms length basis			0	0
18	Mahi Drugs Private Limited	AAICM3271E	Chemwerth Inc	AADCC3781G	Other Related Party	Sale of goods or services		3500	In ordinary course of buisness and in arms length basis			0	-347.83
19	Mahi Drugs Private Limited	AAICM3271E	Chemwerth Inc	AADCC3781G	Other Related Party	Any other transaction	Receipt of business advance	1500	In ordinary course of buisness and in arms length basis			0	0
20	Mahi Drugs Private Limited	AAICM3271E	SMS Pharmaceuticals Ltd	AADC'S2221D	Other Related Party	Purchase of goods or services		35	In ordinary course of buisness and in arms			0	0

									length basis				
21	Mahi Drugs Private Limited	AAICM3271E	SMS Pharmaceuticals Ltd	AADCS2221D	Other Related Party	Sale of goods or services		500	In ordinary course of buisness and in arms length basis			54.65	61.65
Total value of transaction during the reporting period												3197.15	

Details of Impact of Audit Qualification			
Whether results are audited or unaudited		Audited	
Declaration of unmodified opinion or statement on impact of audit qualification		Declaration of unmodified opinion	
Auditor's opinion			
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results		Yes	
	Audit firm's name	Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI	Certificate valid upto
1	Rambabu and Co	Yes	30-06-2027

General information about company		Consolidated
Scrip code*	540679	
NSE Symbol*	HALEOSLABS	
MSEI Symbol*	NOTLISTED	
ISIN*	INE320X01016	
Name of company	Haleos Labs Limited	
Type of company	Main Board	
Class of security	Equity	
Date of start of financial year	01-04-2025	
Date of end of financial year	31-03-2026	
Date of board meeting when results were approved	29-05-2026	
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	22-05-2026	
Description of presentation currency	INR	
Level of rounding	Lakhs	
Reporting Type	Quarterly	
Reporting Quarter	Fourth quarter	
Nature of report standalone or consolidated	Consolidated	
Whether results are audited or unaudited for the quarter ended	Audited	
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Audited	
Segment Reporting	Single segment	
Description of single segment	Bulk Drugs / API's	
Start date and time of board meeting	29-05-2026 14:45	
End date and time of board meeting	29-05-2026 15:45	
Whether cash flow statement is applicable on company	Yes	
Type of cash flow statement	Cash Flow Indirect	
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion	

Financial Results – Ind-AS				
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)	
Date of start of reporting period		01-01-2026	01-04-2025	
Date of end of reporting period		31-03-2026	31-03-2026	
Whether results are audited or unaudited		Audited	Audited	
Nature of report standalone or consolidated		Consolidated	Consolidated	
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.			
1	Income			
	Revenue from operations	7513.91	33379.45	
	Other income	201.49	243.34	
	Total income	7715.4	33622.79	
2	Expenses			
(a)	Cost of materials consumed	3585.99	14669.42	
(b)	Purchases of stock-in-trade	0	0	
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-497.77	-818.45	
(d)	Employee benefit expense	1616.59	6538.25	
(e)	Finance costs	142.04	644.52	
(f)	Depreciation, depletion and amortisation expense	384.89	1546.88	
(g)	Other Expenses			
1	Manufacturing Expenses	1508.02	6642.58	
2	Other Expenses	885.09	1879.95	
	Total other expenses	2393.11	8522.53	
	Total expenses	7624.85	31103.15	
3	Total profit before exceptional items and tax	90.55	2519.64	
4	Exceptional items	0	0	
5	Total profit before tax	90.55	2519.64	
6	Tax expense			
7	Current tax	-103.82	552.18	
8	Deferred tax	159.97	187.42	
9	Total tax expenses	56.15	739.6	
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0	
11	Net Profit Loss for the period from continuing operations	34.4	1780.04	
12	Profit (loss) from discontinued operations before tax	0	0	
13	Tax expense of discontinued operations	0	0	
14	Net profit (loss) from discontinued operation after tax	0	0	
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0	
16	Total profit (loss) for period	34.4	1780.04	
17	Other comprehensive income net of taxes	4.5	11.14	
18	Total Comprehensive Income for the period	38.9	1791.18	
19	Total profit or loss, attributable to			
	Profit or loss, attributable to owners of parent	43.57	1731.2	
	Total profit or loss, attributable to non-controlling interests	-9.17	48.83	
20	Total Comprehensive income for the period attributable to			

	Comprehensive income for the period attributable to owners of parent	48.35	1738.95	
	Total comprehensive income for the period attributable to owners of parent non-controlling interests	-9.45	52.22	
21	Details of equity share capital			
	Paid-up equity share capital	302.33	302.33	
	Face value of equity share capital	10	10	
22	Reserves excluding revaluation reserve		19353.7	
23	Earnings per share			
i	Earnings per equity share for continuing operations			
	Basic earnings (loss) per share from continuing operations	1.44	57.26	
	Diluted earnings (loss) per share from continuing operations	1.44	57.26	
ii	Earnings per equity share for discontinued operations			
	Basic earnings (loss) per share from discontinued operations	0	0	
	Diluted earnings (loss) per share from discontinued operations	0	0	
iii	Earnings per equity share (for continuing and discontinued operations)			
	Basic earnings (loss) per share from continuing and discontinued operations	1.44	57.26	
	Diluted earnings (loss) per share from continuing and discontinued operations	1.44	57.26	
24	Debt equity ratio			Textual Information(1)
25	Debt service coverage ratio			Textual Information(2)
26	Interest service coverage ratio			Textual Information(3)
27	Disclosure of notes on financial results	Textual Information(4)		

Statement of Asset and Liabilities		
Particulars		Year ended (dd-mm-yyyy)
Date of start of reporting period		01-04-2025
Date of end of reporting period		31-03-2026
Whether results are audited or unaudited		Audited
Nature of report standalone or consolidated		Consolidated
	Assets	
1	Non-current assets	
	Property, plant and equipment	26654.18
	Capital work-in-progress	1042.21
	Investment property	0
	Goodwill	0
	Other intangible assets	2.82
	Intangible assets under development	
	Biological assets other than bearer plants	
	Investments accounted for using equity method	
	Non-current financial assets	
	Non-current investments	3.61
	Trade receivables, non-current	0
	Loans, non-current	0
	Other non-current financial assets	
1	Other Financial Assets	340.62
2	Right of Use Assets	114.91
3		
4		
5		
	Details of other non-current financial assets	
	Total of other non-current financial assets	455.53
	Total non-current financial assets	459.14
	Deferred tax assets (net)	
	Other non-current assets	
1	Other Non-Current Assets	971.94
2		
3		
4		
5		
	Details of other non-current assets	
	Total of other non-current assets	971.94
	Total non-current assets	29130.29
2	Current assets	
	Inventories	7982.42
	Current financial asset	
	Current investments	0
	Trade receivables, current	6133.93
	Cash and cash equivalents	120.84
	Bank balance other than cash and cash equivalents	116.09
	Loans, current	0

	Other current financial assets	
1		
2		
3		
4		
5		
	Details of other current financial assets	
	Total of Other current financial assets	
	Total current financial assets	6370.86
	Current tax assets (net)	179.89
	Other current assets	
1	Other Current Assets	1777.38
2		
3		
4		
5		
	Details of other current assets	
	Total of other current assets	1777.38
	Total current assets	16310.55
3	Non-current assets classified as held for sale	
4	Regulatory deferral account debit balances and related deferred tax Assets	
	Total assets	45440.84
	Equity and liabilities	
1	Equity	
	Equity attributable to owners of parent	
	Equity share capital	302.33
	Other equity	21052.45
	Total equity attributable to owners of parent	21354.78
	Non controlling interest	1600.83
	Total equity	22955.61
2	Liabilities	
	Non-current liabilities	
	Non-current financial liabilities	
	Borrowings, non-current	4995.79
	Trade Payables, non-current	
	(A) Total outstanding dues of micro enterprises and small enterprises	
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	
	Total Trade payable	
	Other non-current financial liabilities	
1	Lease Liabilities	80.96
2		
3		
4		
5		
	Details of other non-current financial liabilities	
	Total of other non-current financial liabilities	80.96
	Total non-current financial liabilities	5076.75
	Provisions, non-current	493.36

	Deferred tax liabilities (net)	1287.37
	Deferred government grants, Non-current	0
	Other non-current liabilities	
1		
2		
3		
4		
5		
	Details of other non-current liabilities	
	Total of other non-current liabilities	
	Total non-current liabilities	6857.48
	Current liabilities	
	Current financial liabilities	
	Borrowings, current	5889.46
	Trade Payables, current	
	(A) Total outstanding dues of micro enterprises and small enterprises	104.59
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	6036.02
	Total Trade payable	6140.61
	Other current financial liabilities	
1	Lease Liabilities	87.59
2	Other Financial Liabilities	1707.38
3		
4		
5		
	Details of other current financial liabilities	
	Total of other current financial liabilities	1794.97
	Total current financial liabilities	13825.04
	Other current liabilities	
1	Other Current Liabilities	1613.82
2		
3		
4		
5		
	Details of other current liabilities	
	Total of other current liabilities	1613.82
	Provisions, current	188.89
	Current tax liabilities (Net)	
	Deferred government grants, Current	
	Total current liabilities	15627.75
3	Liabilities directly associated with assets in disposal group classified as held for sale	
4	Regulatory deferral account credit balances and related deferred tax liability	
	Total liabilities	22485.23
	Total equity and liabilities	45440.84
	Disclosure of notes on assets and liabilities	

Other Comprehensive Income			
Date of start of reporting period		01-01-2026	01-04-2025
Date of end of reporting period		31-03-2026	31-03-2026
Whether results are audited or unaudited		Audited	Audited
Nature of report standalone or consolidated		Consolidated	Consolidated
	Other comprehensive income [Abstract]		
1	Amount of items that will not be reclassified to profit and loss		
	Total Amount of items that will not be reclassified to profit and loss		
2	Income tax relating to items that will not be reclassified to profit or loss	-6.39	-15.52
3	Amount of items that will be reclassified to profit and loss		
	Total Amount of items that will be reclassified to profit and loss		
4	Income tax relating to items that will be reclassified to profit or loss	1.89	4.38
5	Total Other comprehensive income	4.50	11.14

Cash flow statement, indirect		
Particulars		Year ended (dd-mm-yyyy)
Date of start of reporting period		01-04-2025
Date of end of reporting period		31-03-2026
Whether results are audited or unaudited		Audited
Nature of report standalone or consolidated		Consolidated
Part I	Blue color marked fields are non-mandatory.	
1	Statement of cash flows	
	Cash flows from used in operating activities	
	Profit before tax	2519.64
2	Adjustments for reconcile profit (loss)	
	Adjustments for finance costs	0
	Adjustments for decrease (increase) in inventories	-1242.64
	Adjustments for decrease (increase) in trade receivables, current	784.41
	Adjustments for decrease (increase) in trade receivables, non-current	0
	Adjustments for decrease (increase) in other current assets	-4429
	Adjustments for decrease (increase) in other non-current assets	-584.21
	Adjustments for other financial assets, non-current	-14.97
	Adjustments for other financial assets, current	-0.31
	Adjustments for other bank balances	0
	Adjustments for increase (decrease) in trade payables, current	914.82
	Adjustments for increase (decrease) in trade payables, non-current	0
	Adjustments for increase (decrease) in other current liabilities	4754.24
	Adjustments for increase (decrease) in other non-current liabilities	0
	Adjustments for depreciation and amortisation expense	1546.89
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	0
	Adjustments for provisions, current	0
	Adjustments for provisions, non-current	0
	Adjustments for other financial liabilities, current	-57.95
	Adjustments for other financial liabilities, non-current	0
	Adjustments for unrealised foreign exchange losses gains	0
	Adjustments for dividend income	0
	Adjustments for interest income	0
	Adjustments for share-based payments	0
	Adjustments for fair value losses (gains)	0.12
	Adjustments for undistributed profits of associates	0
	Other adjustments for which cash effects are investing or financing cash flow	0
	Other adjustments to reconcile profit (loss)	-43.03
	Other adjustments for non-cash items	-39.32
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships	0
	Total adjustments for reconcile profit (loss)	1589.05
	Net cash flows from (used in) operations	4108.69
	Dividends received	0
	Interest paid	-241.55
	Interest received	-7.3
	Income taxes paid (refund)	650

	Other inflows (outflows) of cash	29.41
	Net cash flows from (used in) operating activities	3722.35
3	Cash flows from used in investing activities	
	Cash flows from losing control of subsidiaries or other businesses	0
	Cash flows used in obtaining control of subsidiaries or other businesses	0
	Other cash receipts from sales of equity or debt instruments of other entities	0
	Other cash payments to acquire equity or debt instruments of other entities	0
	Other cash receipts from sales of interests in joint ventures	0
	Other cash payments to acquire interests in joint ventures	0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0
	Proceeds from sales of property, plant and equipment	4.52
	Purchase of property, plant and equipment	5786.21
	Proceeds from sales of investment property	0
	Purchase of investment property	0
	Proceeds from sales of intangible assets	0
	Purchase of intangible assets	0
	Proceeds from sales of intangible assets under development	0
	Purchase of intangible assets under development	0
	Proceeds from sales of goodwill	0
	Purchase of goodwill	0
	Proceeds from biological assets other than bearer plants	0
	Purchase of biological assets other than bearer plants	0
	Proceeds from government grants	0
	Proceeds from sales of other long-term assets	0
	Purchase of other long-term assets	0
	Cash advances and loans made to other parties	0
	Cash receipts from repayment of advances and loans made to other parties	0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts	0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0
	Dividends received	0
	Interest received	7.25
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	-15.2
	Net cash flows from (used in) investing activities	-5789.64
4	Cash flows from used in financing activities	
	Proceeds from changes in ownership interests in subsidiaries	0
	Payments from changes in ownership interests in subsidiaries	0
	Proceeds from issuing shares	0
	Proceeds from issuing other equity instruments	0
	Payments to acquire or redeem entity's shares	0
	Payments of other equity instruments	0
	Proceeds from exercise of stock options	0
	Proceeds from issuing debentures notes bonds etc	0
	Proceeds from borrowings	4016.02
	Repayments of borrowings	1528.83
	Payments of lease liabilities	70.84
	Dividends paid	45.35

	Interest paid	233.16
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) financing activities	2137.84
	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes	70.55
5	Effect of exchange rate changes on cash and cash equivalents	
	Effect of exchange rate changes on cash and cash equivalents	0
	Net increase (decrease) in cash and cash equivalents	70.55
	Cash and cash equivalents cash flow statement at beginning of period	50.29
	Cash and cash equivalents cash flow statement at end of period	120.84

Details of Impact of Audit Qualification			
Whether results are audited or unaudited		Audited	
Declaration of unmodified opinion or statement on impact of audit qualification		Declaration of unmodified opinion	
Auditor's opinion			
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Consolidated results		Yes	
	Audit firm's name	Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI	Certificate valid upto
1	Rambabu and Co	Yes	30-06-2027